Safi U Khan1, Haris Riaz2, Hammad Rahman3, Muhammad U Khan4, Muhammad Shahzeb Khan5, Mohamad Alkhouli6, Edo Kaluski7, Thorsten M Leucker8, Michael J Blaha8. 1. Department of Medicine, West Virginia University, Morgantown, WV, USA. Electronic address: safinmc@gmail.com. 2. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. 3. Department of Medicine, Guthrie Health System, Robert Packer Hospital, Sayre, PA, USA. 4. Department of Medicine, West Virginia University, Morgantown, WV, USA. 5. Department of Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA. 6. Department of Cardiovascular Medicine, West Virginia University, Morgantown, WV, USA. 7. Department of Cardiovascular Medicine, Guthrie Health System, Robert Packer Hospital, Sayre, PA, USA. 8. Division of Cardiology, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: The objective of this study was to investigate whether baseline low-density lipoprotein cholesterol (LDL-C) levels influence total and cardiovascular mortality reduction associated with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy. METHODS: In this meta-analysis, 9 randomized controlled trials were selected using Medline, Embase, and CENTRAL until November 2018. Analyses were stratified by mean baseline LDL-C (<100 mg/dL and ≥ 100 mg/dL). Stepwise prespecified sensitivity analyses were performed after excluding the SPIRE trials and by regrouping ODYSSEY OUTCOME mortality data according to the baseline LDL-C (< and ≥100 mg/dL). RESULTS: In 83,321 patients, PCSK9 inhibitor therapy was not associated with a reduction in the risk of all-cause mortality (relative risk [RR], 0.94, 95% confidence interval [CI], 0.81-1.09, P = .41). These results remained consistent after excluding the SPIRE trials (RR, 0.89, 95% CI, 0.75-1.05, P = .18). However, the RR varied by baseline LDL-C, with significant RR reduction only in patients with LDL-C ≥ 100 mg/dL (RR, 0.39, 95% CI, 0.20-0.76) (P-interaction = .01). Meta-regression showed RR of 0.97 for all-cause mortality per 1 mg/dL higher baseline LDL-C (95% CI, 0.94-0.99). PCSK9 inhibitor therapy showed no significant effect on cardiovascular mortality, with no effect when excluding the SPIRE trials. However, after regrouping ODYSSEY OUTCOME estimates, there was a significant reduction in cardiovascular mortality restricted to patients with LDL-C ≥ 100 mg/dL (RR, 0.67, 95% CI, 0.51-0.87) (P-interaction = .006). CONCLUSION: PCSK9 inhibitor therapy on a background statin treatment may reduce the risk of total and cardiovascular mortality in patients with baseline LDL-C ≥ 100 mg/dL. These results support current guidelines reserving PCSK9 inhibitors for high-risk patients with residually high LDL-C.
BACKGROUND: The objective of this study was to investigate whether baseline low-density lipoprotein cholesterol (LDL-C) levels influence total and cardiovascular mortality reduction associated with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy. METHODS: In this meta-analysis, 9 randomized controlled trials were selected using Medline, Embase, and CENTRAL until November 2018. Analyses were stratified by mean baseline LDL-C (<100 mg/dL and ≥ 100 mg/dL). Stepwise prespecified sensitivity analyses were performed after excluding the SPIRE trials and by regrouping ODYSSEY OUTCOME mortality data according to the baseline LDL-C (< and ≥100 mg/dL). RESULTS: In 83,321 patients, PCSK9 inhibitor therapy was not associated with a reduction in the risk of all-cause mortality (relative risk [RR], 0.94, 95% confidence interval [CI], 0.81-1.09, P = .41). These results remained consistent after excluding the SPIRE trials (RR, 0.89, 95% CI, 0.75-1.05, P = .18). However, the RR varied by baseline LDL-C, with significant RR reduction only in patients with LDL-C ≥ 100 mg/dL (RR, 0.39, 95% CI, 0.20-0.76) (P-interaction = .01). Meta-regression showed RR of 0.97 for all-cause mortality per 1 mg/dL higher baseline LDL-C (95% CI, 0.94-0.99). PCSK9 inhibitor therapy showed no significant effect on cardiovascular mortality, with no effect when excluding the SPIRE trials. However, after regrouping ODYSSEY OUTCOME estimates, there was a significant reduction in cardiovascular mortality restricted to patients with LDL-C ≥ 100 mg/dL (RR, 0.67, 95% CI, 0.51-0.87) (P-interaction = .006). CONCLUSION:PCSK9 inhibitor therapy on a background statin treatment may reduce the risk of total and cardiovascular mortality in patients with baseline LDL-C ≥ 100 mg/dL. These results support current guidelines reserving PCSK9 inhibitors for high-risk patients with residually high LDL-C.
Authors: T R Pedersen; J Kjekshus; K Berg; T Haghfelt; O Faergeman; G Faergeman; K Pyörälä; T Miettinen; L Wilhelmsen; A G Olsson; H Wedel Journal: Atheroscler Suppl Date: 2004-10 Impact factor: 3.235
Authors: Dhruv S Kazi; Joanne Penko; Pamela G Coxson; Andrew E Moran; Daniel A Ollendorf; Jeffrey A Tice; Kirsten Bibbins-Domingo Journal: JAMA Date: 2017-08-22 Impact factor: 56.272
Authors: Dirk J Blom; Tomas Hala; Michael Bolognese; Michael J Lillestol; Phillip D Toth; Lesley Burgess; Richard Ceska; Eli Roth; Michael J Koren; Christie M Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae B Kim; Rob Scott; Scott M Wasserman; Evan A Stein Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Paul M Ridker; James Revkin; Pierre Amarenco; Robert Brunell; Madelyn Curto; Fernando Civeira; Marcus Flather; Robert J Glynn; Jean Gregoire; J Wouter Jukema; Yuri Karpov; John J P Kastelein; Wolfgang Koenig; Alberto Lorenzatti; Pravin Manga; Urszula Masiukiewicz; Michael Miller; Arend Mosterd; Jan Murin; Jose C Nicolau; Steven Nissen; Piotr Ponikowski; Raul D Santos; Pamela F Schwartz; Handrean Soran; Harvey White; R Scott Wright; Michal Vrablik; Carla Yunis; Charles L Shear; Jean-Claude Tardif Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Erik Stroes; David Colquhoun; David Sullivan; Fernando Civeira; Robert S Rosenson; Gerald F Watts; Eric Bruckert; Leslie Cho; Ricardo Dent; Beat Knusel; Allen Xue; Rob Scott; Scott M Wasserman; Michael Rocco Journal: J Am Coll Cardiol Date: 2014-03-30 Impact factor: 24.094
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: Alberto Cordero; Moisés Rodríguez-Mañero; Lorenzo Fácila; M Rosa Fernández-Olmo; Manuel J Gómez-Martínez; Alfonso Valle; Jose Mª Castellano; Miriam Martín Toro; José Seijas-Amigo; Alvaro Vicedo; José R González-Juanatey Journal: J Diabetes Metab Disord Date: 2020-06-01
Authors: Matthew T Roe; Qian H Li; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Shaun G Goodman; Robert A Harrington; J Wouter Jukema; Patricio Lopez-Jaramillo; Renato D Lopes; Michael J Louie; Patrick M Moriarty; Michael Szarek; Robert Vogel; Harvey D White; Andreas M Zeiher; Marie T Baccara-Dinet; Ph Gabriel Steg; Gregory G Schwartz Journal: Circulation Date: 2019-09-02 Impact factor: 29.690